Xtant Medical (XTNT) Holdings announced the commercial launch of its next-generation innovative synthetic bone graft in the nanOss line, Strata. Strata is available in compression-resistant preformed strips and prehydrated moldable grafts. Sean Browne, President and CEO of Xtant Medical, stated, “By building on the clinical success of our nanOss products, Strata further demonstrates our commitment to innovation in regenerative medicine. We are excited to introduce this new technology to help our surgeon customers improve the surgical outcomes of their patients.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XTNT:
- Xtant Medical Sells Assets to Companion Spine
- Xtant Medical Reports Strong Q3 2025 Results
- Xtant Medical Holdings’ Earnings Call: Positive Growth Amid Challenges
- Xtant Medical Holdings: Buy Rating Affirmed on Strong Financial Performance and Strategic Growth Potential
- Xtant Medical price target lowered to $1.50 from $2 at BTIG